Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $4.60.
A number of equities research analysts recently issued reports on CLSD shares. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Clearside Biomedical in a research note on Wednesday, March 13th. HC Wainwright reduced their price objective on Clearside Biomedical from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price objective on shares of Clearside Biomedical in a research report on Monday, May 13th. StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, May 10th. Finally, Wedbush reiterated an “outperform” rating and set a $4.00 price target (down from $5.00) on shares of Clearside Biomedical in a report on Wednesday, March 13th.
Check Out Our Latest Stock Report on Clearside Biomedical
Institutional Trading of Clearside Biomedical
Clearside Biomedical Stock Performance
CLSD opened at $1.24 on Tuesday. Clearside Biomedical has a one year low of $0.65 and a one year high of $2.12. The company has a market cap of $92.67 million, a price-to-earnings ratio of -2.25 and a beta of 2.43. The business’s fifty day moving average is $1.27 and its two-hundred day moving average is $1.34.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.98 million. During the same period in the prior year, the business earned ($0.15) EPS. On average, analysts predict that Clearside Biomedical will post -0.63 EPS for the current fiscal year.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
- Five stocks we like better than Clearside Biomedical
- 5 discounted opportunities for dividend growth investors
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Most Volatile Stocks, What Investors Need to Know
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.